Trial Profile
A Phase 1 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Vorolanib (Primary) ; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Tyrogenex; Xcovery Vision
- 01 Jul 2017 Results published in the JAMA Ophthalmology
- 08 Jun 2017 Results published in a Tyrogenex media release.
- 08 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.